Post Sclerotherapy
Sclerolucent - Targeted Fade Cream
$58.00
Sclerolucent Alpha Arbutin targeted fade cream combines Alpha Arbutin, Jojoba Oil, Squalane and Sodium Hyaluronate in a proprietary non-hydroquinone skin brightening blend. Sclerolucent can reduce hyperpigmentation and fade bronzing and skin discoloration while nourishing and conditioning the skin. Sclerolucent is 2X more effective than Kojic Acid and Phytic Acid (Sclerovase) and 4x effective than hydroquinone.
- Sclerolucent targeted fade cream combines Alpha Arbutin, Jojoba Oil, Squalane and Sodium Hyaluronate in a proprietary non-hydroquinone skin brightening blend. Sclerolucent can reduce hyperpigmentation and fade bronzing and skin discoloration while nourishing and conditioning the skin.
- Apply twice daily or as directed by a vein specialist or skin care professional. Clean skin and apply onto post-sclerotherapy areas or areas affected with post-inflammatory hyperpigmentation. Avoid sun exposure.
- Alpha Arbutin, Jojoba Oil, Squalane, and Sodium Hyaluronate
Scler-X - Post-Inflammatory Hyperpigmentation Relief Complex
$38.00
The proprietary blend in Scler-X® is formulated to reduce tissue inflammation in general and tissue injury, pain, swelling after sclerotherapy and post-inflammatory hyperpigmentation.
- Scler-X® is a proprietary blend of products that was developed by two Vein Specialists and a plastic surgeon and skin specialist. Pine bark extract is anti-inflammatory and reduces oxidative damage that causes inflammation and swelling. Grape seed extract treats venous insufficiency, tissue swelling from inflammation and improves skin elasticity. Bilberry has many antioxidant properties. The proprietary blend in Scler-X® is formulated to reduce tissue inflammation in general and tissue injury, pain, swelling after sclerotherapy and post-inflammatory hyperpigmentation.
- Take two capsules daily with food.
- Swell-X® is a physician formulated product that contains a proprietary blend of Grape Seed Extract 95%, Pine Bark Extract, and Bilberry Extract 25%.